The newly developed CXCR4 antagonist, Peptide R (Pep R), reduced the growth and improved the efficacy of conventional chemo (CT) or chemo-radiotherapy (RT-CT) in a HCT116 human colon cancer model. The gene discussed is CXCR4; the disease is colonic neoplasm.